A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- BeiGene USA, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03150862
- Locations
- 🇺🇸
UCLA Neuro-Oncology, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute at Health One, Denver, Colorado, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
© Copyright 2024. All Rights Reserved by MedPath